<- Go Home
SIGA Technologies, Inc.
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security market in the United States. The company’s lead product is TPOXX, an antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. was incorporated in 1995 and is headquartered in New York, New York.
Market Cap
$313.4M
Volume
483.8K
Cash and Equivalents
$145.6M
EBITDA
$21.2M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$40.8M
Profit Margin
43.56%
52 Week High
$9.62
52 Week Low
$4.09
Dividend
13.73%
Price / Book Value
N/A
Price / Earnings
15.61
Price / Tangible Book Value
2.08
Enterprise Value
N/A
Enterprise Value / EBITDA
N/A
Operating Income
$20.6M
Return on Equity
11.00%
Return on Assets
5.53
Cash and Short Term Investments
$145.6M
Debt
$601.0K
Equity
$151.6M
Revenue
$93.8M
Unlevered FCF
$59.4M
Sector
Pharmaceuticals
Category
N/A